Pharma Tech Outlook Names Kineta Company of the Year!
Date & Time:
September 30, 10:00 AM PDT / 1:00 PM EDT
Webinar: Details provided upon RSVP approval
About the Event:
When a leading publication in your industry singles you out for excellence, you know you’re doing something right. Clearly Kineta is doing a lot of things right to be named one of the top 10 immunotherapy companies of 2020 and Company of the Year by Pharma Tech Outlook magazine.
In making their decision the magazine highlighted Kineta’s progress in three key areas:
- The development of a novel anti-VISTA antibody for the treatment of solid cancerous tumors by turning immuno suppressive cells into immuno reactive cells.
- Its partnership with Genentech to develop nicotinic acetylcholine receptor antagonists that have the potential to treat chronic pain in a non-addictive way.
- Their work with the Wellcome Trust to stop the spread of Lassa fever with LHF535, a first-in-class antiviral that recently completed Phase 1 studies in healthy volunteers.
Kineta CEO, Shawn Iadonato welcomed the award saying, “This recognition speaks to the quality of the scientific team and reflects the innovative work at the company as we look to develop novel best in class immunotherapies for patients.” Click here to read the full article.
Join us on September 30, to hear from Dr. Iadonato and his team about this and other news from Kineta.
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.